Dynavax Technologies Corp... (DVAX)
| Bid | 11.35 |
| Market Cap | 1.41B |
| Revenue (ttm) | 277.25M |
| Net Income (ttm) | 27.31M |
| EPS (ttm) | 0.2 |
| PE Ratio (ttm) | 57.55 |
| Forward PE | 21.02 |
| Analyst | Buy |
| Ask | 11.78 |
| Volume | 1,243,356 |
| Avg. Volume (20D) | 2,513,037 |
| Open | 11.72 |
| Previous Close | 11.75 |
| Day's Range | 11.37 - 11.63 |
| 52-Week Range | 9.74 - 14.63 |
| Beta | 1.26 |
About DVAX
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a coll...
Analyst Forecast
According to 3 analyst ratings, the average rating for DVAX stock is "Buy." The 12-month stock price forecast is $31, which is an increase of 169.33% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Dynavax Technologies: A Post-Earnings Assessment With Growing Market ShareDynavax Technologies posted solid Q4 results and FY 2025 guidance late in February, with Heplisav-B driving revenue growth and profitability. Heplisav-B's market share continues to grow due to its sup...
2 months ago · seekingalpha.com
Dynavax Technologies Corporation (DVAX) Q4 2024 Earnings Call TranscriptDynavax Technologies Corporation (NASDAQ:DVAX ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Paul Cox - Vice President, Investor Relations & Corporate Communicati...
